You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Claims for Patent: 11,896,572

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,896,572

Title:	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:	Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):	Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François DUBUISSON
Assignee:	Flamel Ireland Ltd
Application Number:	US18/231,581
Patent Claims:	1. A pharmaceutical composition comprising: immediate release particles, each of which comprises: a core consisting of microcrystalline cellulose; and a sodium oxybate loaded layer covering the core and containing a binder comprising povidone, wherein the immediate release particles have a volume mean diameter of 150 to 400 microns; delayed release particles having a pH trigger, each delayed release particle comprising: a core consisting of microcrystalline cellulose; a sodium oxybate loaded layer covering the core of each delayed release particle and containing a binder comprising povidone; and a coating covering the sodium oxybate loaded layer of each delayed release particle, wherein the coating consists essentially of hydrogenated vegetable oil, methacrylic acid copolymer type C and methacrylic acid copolymer type B, wherein a weight ratio of the hydrogenated vegetable oil to the copolymers types B and C is from 0.4 to 4, and wherein the coating is from 10 to 50% of the weight of the delayed release particles, and wherein the delayed release particles have a volume mean diameter of 200 to 800 microns; a suspending or viscosifying agent comprising 2% to 5% by weight of the composition, the suspending or viscosifying agent being a mixture of xanthan gum, carrageenan and hydroxyethylcellulose; and an acidifying agent comprising 1.2% to 5% by weight of the composition, the acidifying agent being malic acid, wherein the composition comprises from 3.0 to 12.0 g of sodium oxybate, wherein a ratio of sodium oxybate in the immediate release particles and the delayed release particles is from 40/60 to 60/40, wherein the composition is in the form of a powder that is intended to be suspended in water prior to oral administration, and wherein the suspending or viscosifying agent and the acidifying agent are separate from the immediate release particles and the delayed release particles.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.